Skip to main content

Exosome-based detection of EGFR T790M in plasma and pleural fluid of prospectively enrolled non-small cell lung cancer patients after first-line tyrosine kinase inhibitor therapy.

Kim Y, Shin S, Lee KA

Publication: Cancer Cell Int (2021) • Vol 21 • Page 50PMID: 33435996View on PubMed

Purpose

This paper compared the detection of epidermal growth factor receptor (EGFR) mutations in plasma using three methods and in the pleural fluid supernatant, exosomes, and cellular pellets collected from non-small cell lung cancer (NSCLC) patients. The read counts and DNA size were also compared in pleural fluid exosomes isolated using two different methods.

Conclusion

While all three assays had 100% specificity for the EGFR activating (L858R or exon 19 deletion) and resistance mutations (T790M) in plasma, the sensitivity for the mutations was highest using ddPCR analysis of both cfDNA and exosomal total nucleic acid (exoTNA), followed by next-generation sequencing (NGS) of cfDNA and exoTNA. The sensitivity of pleural fluid exosomes was higher than that of pleural fluid cfDNA for the T790M mutation but the specificity of both methods was 100%. exoTNA read counts were higher when DNA was extracted using the MagMAX Total Nucleic Acid Isolation Kit rather than the QIAamp DNA Mini Kit. High molecular weight DNA (10-15 kb long) was more abundant in exosomes from pleural fluids than from the cfDNA or the cellular pellet DNA and this was most evident when isolation of exoTNA was performed with the MagMAX Total Nucleic Acid Isolation Kit.

Studies (2)

Purpose

This study compared the detection of EGFR mutations using three methods (ddPCR, Cobas EGFR Mutation Test v2, and NGS) in cfDNA and exoTNA isolated from the plasma of NSCLC patients. Blood was collected from 54 patients with NSCLC that had progressed on EGFR inhibitor therapy into Roche Cell-Free DNA Blood Collection Tubes. Plasma was isolated by centrifugation at 12000 x g for 10 min followed by 16,000 x g for 10 min and stored at -80°C.  Debris was removed from pleural fluid by centrifugation at 3000 x g for 15 min. Exosomes were isolated from the plasma and pleural fluid using ExoQuick. cfDNA and exoTNA were extracted using the MagMAX Cell-Free and Total Nucleic Acid Isolation kits, respectively. DNA was quantified on a 3.0 Fluorometer using the Qubit dsDNA HS Assay Kit and reverse transcribed using the SuperScript VILO cDNA Synthesis Kit. DNA fragments sizes were assessed using a Tapestation. Mutational status was investigated in plasma cfDNA using the real-time PCR Cobas z 480 Analyzer and in plasma cfDNA and exoTNA using the ddPCR based Prime-PCR EGFR Exon 19 Deletions Screening Kit and NGS using the Oncomine Pan-Cancer Cell-Free Assay.

Summary of Findings

The plasma cfDNA levels measured by the Cobas z 480 Analyzer were higher than plasma cfDNA and exoTNA quantified by ddPCR (16.8 ng versus 10.3 ng and 11.41 ng, P=0.0002).  Activating mutations (L858R or exon 19 deletion) and resistance mutations (T790M) were found by two or more cfDNA assays or in tumor and one or more cfDNA assay in 43 and 17 patients, respectively. The highest sensitivity for these activating mutations was obtained using ddPCR analysis of both cfDNA and exoTNA (41/43, 95.3%) followed by NGS of cfDNA and exoTNA (30/32, 93.8%) and Cobas quantification of cfDNA (40/43, 93%). Importantly, the specificity of all three assays for activating mutations was 100% with each of the patients that were wildtype for activating mutations identified using each of the methods (11/11 for ddPCR and Cobas, 3/3 for NGS). The highest sensitivity for the T790M mutation was also found using ddPCR of cfDNA and exoTNA (15/17, 98.2%) followed by NGS of cfDNA and exoTNA (14/15, 93.3%) and Cobas of cfDNA (11/17, 64.7%). All patients that were wildtype for the T790M mutation were properly classified using each of the three methods (37/37 by Cobas and ddPCR, 23/23 by NGS). NGS was able to find additional mutations in some patients.

  • Biospecimens

    FluidPlasma
  • Preservation Types

    Frozen
  • Diagnoses

    NeoplasticCarcinoma
  • Platforms

    DNANext generation sequencing
    DNAReal-time qPCR
    DNADigital PCR
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    Biospecimen Aliquots and ComponentsBlood and blood products
    Plasma
    Plasma exosomes
    Digital PCR SpecificTargeted nucleic acid
    EGFR L858R or exon 19 deletion
    EGFR T790M
    Digital PCR SpecificTechnology platform
    NGS
    Real-time PCR (Cobas)
    Next generation sequencing SpecificTargeted nucleic acid
    EGFR L858R or exon 19 deletion
    EGFR T790M
    Real-time qPCR SpecificTargeted nucleic acid
    EGFR L858R or exon 19 deletion
    EGFR T790M